Skip to main content

Table 1 Summary of the characteristics of the included studies

From: Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Author/year

N

Physical status

TNM stage

Intervention

Duration (cycle)

Outcomes

Methods score

T

C

T

C

Ye L et al., 2017 [25]

30

30

NR

IIIb-IV

TP + XAPI (60 ml/d, d1–10)

TP

1

①②③④⑤⑥⑦

8

Hu XL et al., 2017 [26]

53

53

NR

IIIb-IV

GP + XAPI (20 ml/d, d1–15)

GP

4

①③④⑤⑦⑧⑨⑩

9

Gu N et al., 2016 [27]

39

39

NR

III-IV

GP + XAPI (22 ml/d, d1–22)

GP

1

â‘ â‘¡

7

Liu JR et al., 2016 [28]

30

30

ZPS ≤ 3

IIIb-IV

GP + XAPI (40 ml/d, d1–14)

GP

2

â‘ 

7

Li XG et al., 2016 [29]

64

58

KPS > 70

IIIb-IV

GP + XAPI (80 ml/d, d1–8)

GP

4

①③④⑤

7

Li QL et al., 2016 [30]

36

36

KPS > 70

IIIb-IV

GP + XAPI (40–60 ml/d, d1–15)

GP

2

①②③④⑤⑥⑦⑧

9

Yao J, 2016 [31]

53

53

KPS ≥ 61

IIIb-IV

TP + XAPI (20 ml/d, d1–21)

TP

2

①③④⑤⑪

7

Song Y et al., 2016 [32]

40

40

NR

IIIb-IV

GP/NP + XAPI (40 ml/d, d1–15)

GP/NP

1

①③④⑤⑥⑨⑩

8

Li YL et al., 2015 [33]

33

32

KPS ≥ 60

IIIb-IV

TP + XAPI (60 ml/d, d1–15)

TP

2

①②③④⑤⑥⑨⑩⑪

8

Mei CR et al., 2015 [34]

30

33

KPS ≥ 60

IIIb-IV

TP + XAPI (20 ml/d, d1–14)

TP

2

①②③④⑤⑥⑦⑧

8

Shen LW et al., 2015 [35]

28

28

KPS ≥ 60

III-IV

TP + XAPI (40–60 ml/d, d1–15)

TP

2

①③④⑤⑪

8

Ai L et al., 2015 [36]

33

32

KPS ≥ 60

IIIb-IV

TP + XAPI (60 ml/d, d1–14)

TP

2

①②⑨

7

Shi L et al., 2015 [37]

26

26

NR

IIIb-IV

TP + XAPI (60 ml/d, d1–14)

TP

3

â‘ 

7

Xia GA, 2013 [38]

39

39

KPS ≥ 50

IIIb-IV

TP + XAPI (40 ml/d, d1–14)

TP

2

â‘ â‘¡

7

Fang H et al., 2013 [39]

43

43

KPS > 70

IIIb-IV

GP + XAPI (4 ml/d, d1–8)

GP

3

①③④⑤⑥

9

Yang WQ et al., 2013 [40]

37

37

PS 0–2

IIIb-IV

DP + XAPI (60 ml/d, d1–28)

DP

2

①②③④⑤⑥⑦⑧

9

Zhang FY et al., 2011 [41]

24

24

KPS > 50

IIIb-IV

GP + XAPI (40–60 ml/d, d1–15)

GP

2

①②③④⑤⑫

8

Yang H et al., 2011 [42]

30

30

KPS ≥ 60

IIIb-IV

NP + XAPI (60 ml/d, d1–7)

NP

2

â‘ â‘¡

7

Bai RL, 2010 [43]

36

36

KPS ≥ 60

IIIa-IV

NP + XAPI (60 ml/d, d1–15)

NP

1

â‘ â‘¡â‘«

7

Li J et al., 2009 [44]

38

38

KPS > 70

IIIb-IV

GP + XAPI (40 ml/d, d1–15)

GP

2

①②③④⑤⑥⑦⑧⑨

8

Wang K et al., 2009 [45]

28

28

KPS > 50

IIIb-IV

NP + XAPI (20–60 ml/d, d1–15)

NP

2

①②③④⑤⑫

8

Wang WY et al., 2009 [46]

27

29

KPS ≥ 70

IIIb-IV

TP + XAPI (80 ml/d, d1–7)

TP

2

â‘ â‘¡â‘«

7

Song CP, 2008 [47]

36

36

KPS ≥ 60

IIIa-IV

NP + XAPI (60 ml/d, d1–15)

NP

2

â‘ â‘¡

7

Huang ZQ et al., 2007 [48]

30

32

KPS ≥ 50

IIIb-IV

GP/TC/NP + XAPI (60 ml/d, d1–15)

GP/TP/NP

2

①②③④⑤⑥⑦⑧⑩⑫

8

  1. NR Not reported, DP Docetaxel plus Cisplatin, GP Gemcitabine plus Cisplatin, NP Navelbine plus Cisplatin, TP Taxol plus Cisplatin; outcomes ① ORR; ② KPS; ③ leukopenia; ④ thrombocytopenia; ⑤ anemia; ⑥ nausea and vomiting; ⑦ liver function; ⑧ kidney function; ⑨ diarrhea; ⑩ constipation; ⑪ fatigue; ⑫ immune function